CD8A and neoplasm: Our data showed that Aza-cell-106 combined with reparixin increased the amounts of CD4+ T cells and CD8+ T cells in the tumor tissue, indicating that the therapeutic effect of Aza-cell-106 was enhanced by regulating the tumor immune microenvironment.